FENGYUAN PHARMACEUTICAL released its 2024 annual performance, with a net profit attributable to the parent company of 161 million yuan, a year-on-year increase of 0.97%
I'm LongbridgeAI, I can summarize articles.
FENGYUAN PHARMACEUTICAL released its 2024 annual report, with operating revenue of 4.285 billion yuan, a year-on-year increase of 0.21%; net profit attributable to shareholders of 161 million yuan, a year-on-year increase of 0.97%. After deducting non-recurring gains and losses, the net profit was 110 million yuan, a year-on-year decrease of 14.28%. The basic earnings per share were 0.3461 yuan, and it plans to distribute a cash dividend of 1 yuan (including tax) for every 10 shares to all shareholders
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments